Inhibiting metalloproteases with PD 166793 in heart failure: Impact on cardiac remodeling and beyond

Cardiovascular Therapeutics

Volumn 26, Issue 1, 2008, Pages 24-37

  Kaludercic, Nina ^a   Lindsey, Merry L ^b   Tavazzi, Barbara ^c   Lazzarino, Giuseppe ^d   Paolocci, Nazareno ^a,e,f  

^a DEPARTMENT OF PATHOLOGY   (United States)

^b UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^c CATHOLIC UNIVERSITY   (Italy)

^d UNIVERSITY OF CATANIA   (Italy)

^e UNIVERSITY OF PERUGIA   (Italy)

^f JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

AMP deaminase; Cardiac energetics; Heart failure; Metalloproteinases; Myocardial fibrosis; PD166793; Ventricular remodeling

Indexed keywords

ACTINONIN; ALPHA 2 MACROGLOBULIN; BATIMASTAT; BISPHOSPHONIC ACID DERIVATIVE; CATHECIN; CP 471 474; CURCUMIN; DOXYCYCLINE HYCLATE; GENISTEIN; ILOMASTAT; MARIMASTAT; MATRIX METALLOPROTEINASE INHIBITOR; METALLOPROTEINASE; N1 [2,2 DIMETHYL 1 [(METHYLAMINO)CARBONYL]PROPYL] N4 HYDROXY 2 (2 METHYLPROPYL)BUTANEDIAMIDE; PD 166793; PEROXYNITRITE; POLYPHENOL; RESVERATROL; RO 28 2653; TETRACYCLINE DERIVATIVE; THROMBOSPONDIN 1; THROMBOSPONDIN 2; TISSUE INHIBITOR OF METALLOPROTEINASE; UNCLASSIFIED DRUG;

ARTHRALGIA; CONGESTIVE HEART FAILURE; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG INHIBITION; DRUG MECHANISM; DRUG SOLUBILITY; DRUG STRUCTURE; ENZYME INHIBITION; HEART FAILURE; HEART INFARCTION; HEART VENTRICLE REMODELING; HUMAN; ISCHEMIC HEART DISEASE; MYALGIA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVIEW;

ANIMALS; ENZYME ACTIVATION; GENE THERAPY; HEART FAILURE; HUMANS; HYDROXAMIC ACIDS; METALLOPROTEASES; OLIGOPEPTIDES; PROTEASE INHIBITORS; VENTRICULAR REMODELING;

EID: 47049121031     PISSN: 17555914     EISSN: 17555922     Source Type: Journal    
DOI: 10.1111/j.1527-3466.2007.00034.x     Document Type: Review

References (84)

1. Ahn K, Sisneros AM, Herman SB, Pan SM, Hupe D, Lee C, Nikam S, Cheng XM, Doherty AM, Schroeder RL, et al 1998) Novel selective quinazoline inhibitors of endothelin converting enzyme-1. Biochem Biophys Res Commun 243 : 184 190.
2. Baker AH, Edwards DR, Murphy G (2002) Metalloproteinase inhibitors: Biological actions and therapeutic opportunities. J Cell Sci 115 : 3719 3727.
3. Birkedal-Hansen H, Moore WG, Bodden MK, Windsor LJ, Birkedal-Hansen B, DeCarlo A, Engler JA (1993) Matrix metalloproteinases: A review. Crit Rev Oral Biol Med 4 : 197 250.
4. Blavier L, Henriet P, Imren S, Declerck YA (1999) Tissue inhibitors of matrix metalloproteinases in cancer. Ann NY Acad Sci 878 : 108 119.
5. Borlaug BA, Kass DA (2006) Mechanisms of diastolic dysfunction in heart failure. Trends Cardiovasc Med 16 : 273 279.
6. Brauer PR (2006) MMPs - role in cardiovascular development and disease. Front Biosci 11 : 447 478.
7. Brower GL, Levick SP, Janicki JS (2007) Inhibition of matrix metalloproteinase activity by ACE inhibitors prevents left ventricular remodeling in a rat model of heart failure. Am J Physiol Heart Circ Physiol 292 : H3057 H3064.
8. Bunning P, Holmquist B, Riordan JF (1983) Substrate specificity and kinetic characteristics of angiotensin converting enzyme. Biochemistry 22 : 103 110.
9. Chakraborti S, Mandal M, Das S, Mandal A, Chakraborti T (2003) Regulation of matrix metalloproteinases: An overview. Mol Cell Biochem 253 : 269 285.
10. Chancey AL, Brower GL, Peterson JT, Janicki JS (2002) Effects of matrix metalloproteinase inhibition on ventricular remodeling due to volume overload. Circulation 105 : 1983 1988.
11. Chapman RE, Scott AA, Deschamps AM, Lowry AS, Stroud RE, Ikonomidis JS, Spinale FG (2003) Matrix metalloproteinase abundance in human myocardial fibroblasts: Effects of sustained pharmacologic matrix metalloproteinase inhibition. J Mo Cell Cardio 35 : 539 548.
12. Chen JM, Nelson FC, Levin JI, Mobilio D, Moy FJ, Nilakantan R, Zask A, Powers R (2000) Structure-based design of a novel, potent, and selective inhibitor for MMP-13 Utilizing NMR spectroscopy and computer-aided molecular design. J Am Chem Soc 122 : 9648 9654.
13. Chirco R, Liu XW, Jung KK, Kim HR (2006) Novel functions of TIMPs in cell signaling. Cancer Metastasis Rev 25 : 99 113.
14. Chow AK, Cena J, Schulz R (2007) Acute actions and novel targets of matrix metalloproteinases in the heart and vasculature. Br J Pharmacol 152 : 189 205.
15. Corcoran ML, Stetler-Stevenson WG (1995) Tissue inhibitor of metalloproteinase-2 stimulates fibroblast proliferation via a cAMP-dependent mechanism. J Biol Chem 270 : 13453 13459.
16. Davis GE, Saunders WB (2006) Molecular balance of capillary tube formation versus regression in wound repair: Role of matrix metalloproteinases and their inhibitors. J Investig Dermatol Symp Proc 11 : 44 56.
17. Delany AM, Brinckerhoff CE (1992) Post-transcriptional regulation of collagenase and stromelysin gene expression by epidermal growth factor and dexamethasone in cultured human fibroblasts. J Cell Biochem 50 : 400 410.
18. Deschamps AM, Spinale FG (2006) Pathways of matrix metalloproteinase induction in heart failure: Bioactive molecules and transcriptional regulation. Cardiovasc Res 69 : 666 676.
19. Ducharme A, Frantz S, Aikawa M, Rabkin E, Lindsey M, Rohde LE, Schoen FJ, Kelly RA, Werb Z, Libby P, et al 2000) Targeted deletion of matrix metalloproteinase-9 attenuates left ventricular enlargement and collagen accumulation after experimental myocardial infarction. J Clin Invest 106 : 55 62.
20. Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2 : 161 174.
21. Engel CK, Pirard B, Schimanski S, Kirsch R, Habermann J, Klingler O, Schlotte V, Weithmann KU, Wendt KU (2005) Structural basis for the highly selective inhibition of MMP-13. Chem Biol 12 : 181 189.
22. Farkas E, Katz Y, Bhusare S, Reich R, Roschenthaler GV, Konigsmann M, Breuer E (2004) Carbamoylphosphonate- based matrix metalloproteinase inhibitor metal complexes: Solution studies and stability constants. Towards a zinc-selective binding group. J Biol Inorg Chem 9 : 307 315.
23. Fernandez-Patron C, Radomski MW, Davidge ST (1999) Vascular matrix metalloproteinase-2 cleaves big endothelin-1 yielding a novel vasoconstrictor. Circ Res 85 : 906 911.
24. Fingleton B (2007) Matrix metalloproteinases as valid clinical targets. Curr Pharm Des 13 : 333 346.
25. Gao CQ, Sawicki G, Suarez-Pinzon WL, Csont T, Wozniak M, Ferdinandy P, Schulz R (2003) Matrix metalloproteinase-2 mediates cytokine-induced myocardial contractile dysfunction. Cardiovasc Res 57 : 426 433.
26. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP (1997) Tissue inhibitors of metalloproteinases: Structure, regulation and biological functions. Eur J Cell Biol 74 : 111 122.
27. Henderson BC, Tyagi SC (2006) Oxidative mechanism and homeostasis of proteinase/antiproteinase in congestive heart failure. J Mol Cell Cardiol 41 : 959 962.
28. Heymans S, Luttun A, Nuyens D, Theilmeier G, Creemers E, Moons L, Dyspersin GD, Cleutjens JP, Shipley M, Angellilo A, et al 1999) Inhibition of plasminogen activators or matrix metalloproteinases prevents cardiac rupture but impairs therapeutic angiogenesis and causes cardiac failure. Nat Med 5 : 1135 1142.
29. Hirohata S, Kusachi S, Murakami M, Murakami T, Sano I, Watanabe T, Komatsubara I, Kondo J, Tsuji T (1997) Time dependent alterations of serum matrix metalloproteinase-1 and metalloproteinase-1 tissue inhibitor after successful reperfusion of acute myocardial infarction. Heart 78 : 278 284.
30. Holmbeck K, Bianco P, Caterina J, Yamada S, Kromer M, Kuznetsov SA, Mankani M, Robey PG, Poole AR, Pidoux I, et al 1999) MT1-MMP-deficient mice develop dwarfism, osteopenia, arthritis, and connective tissue disease due to inadequate collagen turnover. Cell 99 : 81 92.
31. Holmes JW, Borg TK, Covell JW (2005) Structure and mechanics of healing myocardial infarcts. Annu Rev Biomed Eng 7 : 223 253.
32. Ikejiri M, Bernardo MM, Meroueh SO, Brown S, Chang M, Fridman R, Mobashery S (2005) Design, synthesis, and evaluation of a mechanism-based inhibitor for gelatinase A. J Org Chem 70 : 5709 5712.
33. Ikonomidis JS, Barbour JR, Amani Z, Stroud RE, Herron AR, McClister DM, Jr., Camens SE, Lindsey ML, Mukherjee R, Spinale FG (2005) Effects of deletion of the matrix metalloproteinase 9 gene on development of murine thoracic aortic aneurysms. Circulation 112 : I242 I248.
34. Inokubo Y, Hanada H, Ishizaka H, Fukushi T, Kamada T, Okumura K (2001) Plasma levels of matrix metalloproteinase-9 and tissue inhibitor of metalloproteinase-1 are increased in the coronary circulation in patients with acute coronary syndrome. Am Heart J 141 : 211 217.
35. Johnson JL (2007) Matrix metalloproteinases: Influence on smooth muscle cells and atherosclerotic plaque stability. Expert Rev Cardiovasc Ther 5 : 265 282.
36. Jourquin J, Tremblay E, Bernard A, Charton G, Chaillan FA, Marchetti E, Roman FS, Soloway PD, Dive V, Yiotakis A, et al 2005) Tissue inhibitor of metalloproteinases-1 (TIMP-1) modulates neuronal death, axonal plasticity, and learning and memory. Eur J Neurosci 22 : 2569 2578.
37. Kaden JJ, Dempfle CE, Sueselbeck T, Brueckmann M, Poerner TC, Haghi D, Haase KK, Borggrefe M (2003) Time-dependent changes in the plasma concentration of matrix metalloproteinase 9 after acute myocardial infarction. Cardiology 99 : 140 144.
38. Kassiri Z, Oudit GY, Sanchez O, Dawood F, Mohammed FF, Nuttall RK, Edwards DR, Liu PP, Backx PH, Khokha R (2005) Combination of tumor necrosis factor-alpha ablation and matrix metalloproteinase inhibition prevents heart failure after pressure overload in tissue inhibitor of metalloproteinase-3 knock-out mice. Circ Res 97 : 380 390.
39. Lafleur MA, Handsley MM, Edwards DR (2003) Metalloproteinases and their inhibitors in angiogenesis. Expert Rev Mol Med 5 : 1 39.
40. Li YY, McTiernan CF, Feldman AM (1999) Proinflammatory cytokines regulate tissue inhibitors of metalloproteinases and disintegrin metalloproteinase in cardiac cells. Cardiovasc Res 42 : 162 172.
41. Li H, Simon H, Bocan TM, Peterson JT (2000) MMP/TIMP expression in spontaneously hypertensive heart failure rats: The effect of ACE- and MMP-inhibition. Cardiovasc Res 46 : 298 306.
42. Lindsey ML (2004) MMP induction and inhibition in myocardial infarction. Heart Fail Rev 9 : 7 19.
43. Mangani S, Benvenuti M, Moir AJ, Ranieri-Raggi M, Martini D, Sabbatini AR, Raggi A (2007) Characterization of the metallocenter of rabbit skeletal muscle AMP deaminase. Evidence for a dinuclear zinc site. Biochim Biophys Acta 1774 : 312 322.
44. Manginas A, Bei E, Chaidaroglou A, Degiannis D, Koniavitou K, Voudris V, Pavlides G, Panagiotakos D, Cokkinos DV (2005) Peripheral levels of matrix metalloproteinase-9, interleukin-6, and C-reactive protein are elevated in patients with acute coronary syndromes: Correlations with serum troponin I. Clin Cardiol 28 : 182 186.
45. Matrisian LM (1990) Metalloproteinases and their inhibitors in matrix remodeling. Trends Genet 6 : 121 125.
46. McElmurray JH, III., Mukherjee R, New RB, Sampson AC, King MK, Hendrick JW, Goldberg A, Peterson TJ, Hallak H, Zile MR, et al 1999) Angiotensin- converting enzyme and matrix metalloproteinase inhibition with developing heart failure: Comparative effects on left ventricular function and geometry. J Pharmacol Exp Ther 291 : 799 811.
47. McQuibban GA, Gong JH, Tam EM, McCulloch CA, Clark-Lewis I, Overall CM (2000) Inflammation dampened by gelatinase A cleavage of monocyte chemoattractant protein-3. Science 289 : 1202 1206.
48. Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Baskin JM, Deschamps AM, Lowry AS, Escobar GP, Lucas DG, Yarbrough WM, et al 2003) Myocardial infarct expansion and matrix metalloproteinase inhibition. Circulation 107 : 618 625.
49. Murphy G, Stanton H, Cowell S, Butler G, Knauper V, Atkinson S, Gavrilovic J (1999) Mechanisms for pro matrix metalloproteinase activation. APMIS 107 : 38 44.
50. Nagase H, Visse R, Murphy G (2006) Structure and function of matrix metalloproteinases and TIMPs. Cardiovasc Res 69 : 562 573.
51. Newby AC (2006) Matrix metalloproteinases regulate migration, proliferation, and death of vascular smooth muscle cells by degrading matrix and nonmatrix substrates. Cardiovasc Res 69 : 614 624.
52. O'Brien PM, Ortwine DF, Pavlovsky AG, Picard JA, Sliskovic DR, Roth BD, Dyer RD, Johnson LL, Man CF, Hallak H (2000) Structure-activity relationships and pharmacokinetic analysis for a series of potent, systemically available biphenylsulfonamide matrix metalloproteinase inhibitors. J Med Chem 43 : 156 166.
53. Overall CM, Kleifeld O (2006) Towards third generation matrix metalloproteinase inhibitors for cancer therapy. Br J Cancer 94 : 941 946.
54. Overall CM, Wrana JL, Sodek J (1991) Transcriptional and post-transcriptional regulation of 72-kDa gelatinase/type IV collagenase by transforming growth factor-beta 1 in human fibroblasts. Comparisons with collagenase and tissue inhibitor of matrix metalloproteinase gene expression. J Biol Chem 266 : 14064 14071.
55. Page-McCaw A, Ewald AJ, Werb Z (2007) Matrix metalloproteinases and the regulation of tissue remodelling. Nat Rev Mol Cell Biol 8 : 221 233.
56. Paolocci N, Tavazzi B, Biondi R, Gluzband YA, Amorini AM, Tocchetti CG, Hejazi M, Caturegli PM, Kajstura J, Lazzarino G, et al 2006) Metalloproteinase inhibitor counters high-energy phosphate depletion and AMP deaminase activity enhancing ventricular diastolic compliance in subacute heart failure. J Pharmacol Exp Ther 317 : 506 513.
57. Peterson JT (2004) Matrix metalloproteinase inhibitor development and the remodeling of drug discovery. Heart Fail Rev 9 : 63 79.
58. Peterson JT (2006) The importance of estimating the therapeutic index in the development of matrix metalloproteinase inhibitors. Cardiovasc Res 69 : 677 687.
59. Peterson JT, Li H, Dillon L, Bryant JW (2000) Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46 : 307 315.
60. Peterson JT, Hallak H, Johnson L, Li H, O'Brien PM, Sliskovic DR, Bocan TM, Coker ML, Etoh T, Spinale FG (2001) Matrix metalloproteinase inhibition attenuates left ventricular remodeling and dysfunction in a rat model of progressive heart failure. Circulation 103 : 2303 2309.
61. Ranieri-Raggi M, Martini D, Sabbatini AR, Moir AJ, Raggi A (2003) Isolation by zinc-affinity chromatography of the histidine-proline-rich- glycoprotein molecule associated with rabbit skeletal muscle AMP deaminase. Evidence that the formation of a protein-protein complex between the catalytic subunit and the novel component is critical for the stability of the enzyme. Biochim Biophys Acta 1645 : 81 88.
62. Rao BG (2005) Recent developments in the design of specific Matrix Metalloproteinase inhibitors aided by structural and computational studies. Curr Pharm Des 11 : 295 322.
63. Romanic AM, Harrison SM, Bao W, Burns-Kurtis CL, Pickering S, Gu J, Grau E, Mao J, Sathe GM, Ohlstein EH, et al 2002) Myocardial protection from ischemia/ reperfusion injury by targeted deletion of matrix metalloproteinase-9. Cardiovasc Res 54 : 549 558.
64. Rutschow S, Li J, Schultheiss HP, Pauschinger M (2006) Myocardial proteases and matrix remodeling in inflammatory heart disease. Cardiovasc Res 69 : 646 656.
65. Saarialho-Kere UK, Crouch EC, Parks WC (1995) Matrix metalloproteinase matrilysin is constitutively expressed in adult human exocrine epithelium. J Invest Dermatol 105 : 190 196.
66. Samnegard A, Silveira A, Tornvall P, Hamsten A, Ericsson CG, Eriksson P (2006) Lower serum concentration of matrix metalloproteinase-3 in the acute stage of myocardial infarction. J Intern Med 259 : 530 536.
67. Sawicki G, Salas E, Murat J, Miszta-Lane H, Radomski MW (1997) Release of gelatinase A during platelet activation mediates aggregation. Nature 386 : 616 619.
68. Schulz R (2007) Intracellular targets of matrix metalloproteinase-2 in cardiac disease: Rationale and therapeutic approaches. Annu Rev Pharmacol Toxicol 47 : 211 242.
69. Shipp MA, Vijayaraghavan J, Schmidt EV, Masteller EL, D'Adamio L, Hersh LB, Reinherz EL (1989) Common acute lymphoblastic leukemia antigen (CALLA) is active neutral endopeptidase 24.11 ("enkephalinase"): Direct evidence by cDNA transfection analysis. Proc Natl Acad Sci U.S.A 86 : 297 301.
70. Siwik DA, Pagano PJ, Colucci WS (2001) Oxidative stress regulates collagen synthesis and matrix metalloproteinase activity in cardiac fibroblasts. Am J Physiol Cell Physiol : C53 C60.
71. Skotnicki JS, Zask A, Nelson FC, Albright JD, Levin JI (1999) Design and synthetic considerations of matrix metalloproteinase inhibitors. Ann N Y Acad Sci 878 : 61 72.
72. Spinale FG (2007) Myocardial matrix remodeling and the matrix metalloproteinases: Influence on cardiac form and function. Physiol Rev 87 : 1285 1342.
73. Spinale FG, Coker ML, Krombach SR, Mukherjee R, Hallak H, Houck WV, Clair MJ, Kribbs SB, Johnson LL, Peterson JT, et al 1999) Matrix metalloproteinase inhibition during the development of congestive heart failure: Effects on left ventricular dimensions and function. Circ Res 85 : 364 376.
74. Stawowy P, Fleck E (2005) Proprotein convertases furin and PC5: Targeting atherosclerosis and restenosis at multiple levels. J Mol Med 83 : 865 875.
75. Tyagi SC, Matsubara L, Weber KT (1993) Direct extraction and estimation of collagenase(s) activity by zymography in microquantities of rat myocardium and uterus. Clin Biochem 26 : 191 198.
76. Vanhoutte D, Schellings M, Pinto Y, Heymans S (2006) Relevance of matrix metalloproteinases and their inhibitors after myocardial infarction: A temporal and spatial window. Cardiovasc Res 69 : 604 613.
77. Verma RP, Hansch C (2007) Matrix metalloproteinases (MMPs): Chemical-biological functions and (Q)SARs. Bioorg Med Chem 15 : 2223 2268.
78. Webb CS, Bonnema DD, Ahmed SH, Leonardi AH, McClure CD, Clark LL, Stroud RE, Corn WC, Finklea L, Zile MR, et al 2006) Specific temporal profile of matrix metalloproteinase release occurs in patients after myocardial infarction: Relation to left ventricular remodeling. Circulation 114 : 1020 1027.
79. Welker P, Lippert U, Nurnberg W, Kruger-Krasagakes S, Moller A, Czarnetzki BM (1996) Glucocorticoid-induced modulation of cytokine secretion from normal and leukemic human myelomonocytic cells. Int Arch Allergy Immunol 109 : 110 115.
80. Yarbrough WM, Mukherjee R, Brinsa TA, Dowdy KB, Scott AA, Escobar GP, Joffs C, Lucas DG, Crawford FA, Jr., Spinale FG (2003) Matrix metalloproteinase inhibition modifies left ventricular remodeling after myocardial infarction in pigs. J Thorac Cardiovasc Surg 125 : 602 610.
81. Ye S (2006) Influence of matrix metalloproteinase genotype on cardiovascular disease susceptibility and outcome. Cardiovasc Res 69 : 636 645.
82. Ye QZ, Johnson LL, Hupe DJ, Baragi V (1992) Purification and characterization of the human stromelysin catalytic domain expressed in Escherichia coli. Biochemistry 31 : 11231 11235.
83. Ye QZ, Johnson LL, Nordan I, Hupe D, Hupe L (1994) A recombinant human stromelysin catalytic domain identifying tryptophan derivatives as human stromelysin inhibitors. J Med Chem 37 : 206 209.
84. Ye QZ, Johnson LL, Yu AE, Hupe D (1995) Reconstructed 19 kDa catalytic domain of gelatinase A is an active proteinase. Biochemistry 34 : 4702 4708.